1. Field of the Invention
The present invention relates generally to an occlusion device for the closure of physical anomalies like septal apertures, such as patent foramen ovale and other septal and vascular defects.
2. Background Information
A patent foramen ovale (PFO), illustrated in
The foramen ovale serves a desired purpose when a fetus is gestating in utero. Because blood is oxygenated through the umbilical cord, and not through the developing lungs, the circulatory system of a heart in a fetus allows the blood to flow through the foramen ovale as a physiologic conduit for right-to-left shunting. After birth, with the establishment of pulmonary circulation, the increased left atrial blood flow and pressure results in functional closure of the foramen ovale. This functional closure is subsequently followed by anatomical closure of the two over-lapping layers of tissue: septum primum 14 and septum secundum 16. However, a PFO has been shown to persist in a number of adults.
The presence of a PFO is generally considered to have no therapeutic consequence in otherwise healthy adults. Paradoxical embolism via a PFO is considered in the diagnosis for patients who have suffered a stroke or transient ischemic attack (TIA) in the presence of a PFO and without another cause of ischemic stroke. While there is currently no definitive proof for a cause-effect relationship, many studies have confirmed a strong association between the presence of a PFO and the risk for paradoxical embolism or stroke. In addition, there is significant evidence that patients with PFO who have had a cerebral vascular event are at increased risk for future, recurrent cerebrovascular events.
Accordingly, patients with an increased future risk are considered for prophylactic medical therapy to reduce the risk of a recurrent embolic event. These patients are commonly treated with oral anticoagulants, which have the potential for adverse side effects, such as hemorrhaging, hematoma, and interactions with a variety of other drugs. The use of these drugs can alter a person's recovery and necessitate adjustments in a person's daily living pattern.
In certain cases, such as when anticoagulation is contraindicated, surgery may be necessary or desirable to close the PFO. The surgery would typically include suturing a PFO closed by attaching septum secundum to septum primum. This sutured attachment can be accomplished with either an interrupted or a continuous stitch and is a common way a surgeon shuts a PFO under direct visualization.
Umbrella devices and a variety of other similar mechanical closure designs, developed initially for percutaneous closure of atrial septal defects (ASDs), have been used in some instances to close PFOB. These devices have the potential to allow patients to avoid the potential side effects often associated with anticoagulation therapies and the risks of invasive surgery. However, umbrella devices and the like that are designed for ASDs are not optimally suited for use as a PFO closure device.
Currently available designs of septal closure devices present drawbacks, including technically complex implantation procedures. Additionally, there are not insignificant complications due to thrombus, fractures of the components, conduction system disturbances, perforations of heart tissue, and residual leaks. Many devices have high septal profile and may include large-masses of foreign material, which may lead to unfavorable body adaptation of a device. Since ASD devices are designed to occlude a hole, many lack anatomic conformability to the PFO flap-like anatomy. That is, when inserting an ASD device to close a PFO, the narrow opening and the thin flap may form impediments to proper deployment. Even if an occlusive seal is formed, the device maybe deployed in the heart on an angle, which could leave some components not securely seated against the septum, thereby risking thrombus formation due to hemodynamic disturbances. Finally, some septal closure devices are complex to manufacture, which may result in lack of consistency in product performance.
The present invention is designed to address these and other deficiencies of the prior art septal closure devices.
The present invention provides a device for occluding an anatomical aperture, such as a septal defect or a PFO. This occluder includes two sides connected by an intermediate joint. Each of the sides includes at least one wire or other elongate element for structural support (referred to collectively as “wire”), which is arranged to form non-overlapping loops. Each loop has at least one radially-extending segment that is adjacent to a radially-extending segment of another loop. In at least some embodiments, at least one pair of adjacent radially-extending segments is connected. The loops of the device may be of various shapes and sizes. In at least some embodiments, the loops have rounded peripheries. The configuration of the loops and sides of the occluder are varied according to different embodiments of the invention. In some embodiments, at least one of the sides includes a tissue scaffold.
The wires forming the occluders of the present invention may be constructed of various biocompatible materials. In some embodiments, the wires are formed of shape memory materials, e.g., nitinol. In other embodiments, the wires are formed of polymers, bioabsorbable polymers, or combinations thereof.
The occluder according to the present invention is designed such that, when deployed in vivo, the two sides are disposed on opposite sides of the septal tissue surrounding the aperture, i.e., septum primum and septum secundum. Thus, the two sides exert a compressive force on the septal tissue that is distributed along both the outer periphery of the occluder and the radially-extending segments. In at least some embodiments, the radially-extending segments increase the stiffness of the occluder, thereby preventing the occluder from becoming dislodged from its intended delivery site. In at least some embodiments, the flexible, rounded peripheries of the loops prevent the occluder from inflicting trauma upon the septal tissue as the heart contracts. In at least some embodiments of the present invention, the occluder is repositionable and/or retrievable. These and other advantageous features of the present invention will be explained in more detail in connection with the following illustrations.
The present invention provides a device for occluding an aperture within body tissue. In particular and as described in detail below, the occluder of the present invention may be used for closing a PFO in the atrial septum of a heart. Although the embodiments of the invention are described with reference to a PFO, one skilled in the art will recognize that the device and method of the present invention may be used to treat other anatomical conditions. As such, the invention should not be considered limited to any particular anatomical condition.
An occluder according to one embodiment of the present invention is shown in
The occluder 20 is constructed of wire or other elongate element for structural support, referred to collectively as “wire” 25. The wire is arranged to form loops in both the distal 30 and proximal 40 sides of the occluder 20. According to some embodiments of the present invention, several wires 25 are used to construct the occluder 20. According to other embodiments, the occluder may be formed of a tube using, for example, an etching or cutting process to create elongate members. The elongate members have the general structure of a wire, i.e., long and thin, but are not necessarily round. As used herein, the term “wire” is intended to encompass wires and elongate members (whether or not formed by an etched tube).
The wire(s) 25 may be formed of various biocompatible materials. In at least some embodiments, the occluder 20 is formed of shape memory material (e.g., nitinol). The thermal shape memory and/or superelastic properties of shape memory materials, e.g., nitinol, permit the occluder 20 to resume and maintain its intended shape in vivo despite being distorted during the delivery process. In particular embodiments, the occluder 20 is formed of nitinol that is austenitic at body temperature. Alternatively, or additionally, the occluder 20 may be formed of other high-strength super-alloys, such as Hastelloy® (available from Haynes International), Elgiloy®, or MP35N. In still other embodiments, occluder 20 may be formed of a polymer (e.g., plastics), bioabsorbable polymer, or combination of the foregoing.
The distal side 30 of the occluder 20 (also called the “anchor portion”) is shown in
Although the distal side 30 of the occluder 20 shown in
Regardless of the number of loops included in distal side 30, the outer shape of the loops 32 may vary. For example, as illustrated in
As previously mentioned, the wires 25 forming loops 32 are attached at center joint 22. The adjacent segments extend radially outward from center joint 22 at a spacing of approximately 120 degrees apart. The area of septal tissue enclosed by loops 32 provides support for the distal side 30 once the occluder 20 is deployed in vivo. In at least one embodiment of the present invention, a connection is provided between the adjacent segments, e.g., between segments 33a and 31b, between segments 33b and 31c, and between segments 33c and 31a. For example, as shown in
The adjacent segments may be connected in a variety of ways. As previously indicated, the adjacent segments may be welded. The length of the welds 38 may extend along less than the entire radial distance of the adjacent segments. Alternatively, the adjacent segments may be connected with a tube, e.g., a hypo tube, having a smaller diameter than the diameter of the coupled adjacent segments. In such a configuration, the tube holds the segments together by exerting a compressive force against the wires. Numerous additional means of connecting the segments will be apparent to those skilled in the art, e.g., glue, clips, sutures, polymer sleeves, etc., and are considered to be within the scope of the present invention.
As previously indicated, the connections, e.g., welds 38, between adjacent segments provide stiffness to the distal side 30 of the occluder 20. As illustrated in
It should be noted that the inclusion of connections, e.g., welds 38, to increase the stiffness of the distal side 30 necessitates the use of a greater force to maintain the occluder 20 in reduced profile (i.e., in delivery configuration). The delivery system for an occluder 20 including distal side 30 having connections, e.g., welds 38, must, therefore, possess greater radial strength to contain such a configuration.
The proximal side 40 of the occluder 20 is shown in
The wires forming each of loops 42 do not overlap, i.e., they are not intertwined or weaved. In at least one embodiment, illustrated in
Although the proximal side 40 of the occluder 20 shown in
In a manner similar to that described above with regard to the distal side 30, loops 42 of proximal side 40 also include adjacent segments that may be connected. Specifically, segment 43a of loop 42a is adjacent to segment 41b of loop 42b; segment 43b of loop 42b is adjacent to segment 41c of loop 42c; segment 43c of loop 42c is adjacent to segment 41d of loop 42d; segment 43d of loop 42d is adjacent to segment 41e of loop 42e; segment 43e of loop 42e is adjacent to segment 41f of loop 42f; and segment 43f of loop 42f is adjacent to segment 41a of loop 42a. Connections maybe included between any or all of the adjacent segments. The adjacent segments may be connected using any of the connection means previously described, e.g., welds 48. For example, as shown in
As indicated previously and shown in
In other embodiments of the present invention, the intermediate joint 22 may be a spring, e.g., a coil spring. According to these embodiments, the spring is designed to pull the proximal side 40 of occluder 20 closer to the distal side 30, thereby compressing the septal tissue 12 between the distal 30 and proximal 40 sides in vivo. The tension of the spring may be selected such that the occluder 20 accommodates septal tissue of varying thicknesses. When considering the characteristics of the spring, the need to accommodate septal tissue of varying thicknesses and the need to provide sufficient (but not too much) compressive force must be balanced. One skilled in the art will be capable of selecting a spring meeting these criteria for a given application.
In still further embodiments of the present invention, intermediate joint 22 is positioned at an angle 0, as shown in
When intermediate joint 22 is positioned at angle 0, distal side 30 and proximal side 40 of occluder 20 may be configured such that they are either directly opposing or, as shown in
When an intermediate joint 22 at angle 0 is included in occluder 20, a marker is required to properly orient the occluder 20 in its intended in vivo delivery location. For example, platinum wire may be wrapped around one of loops 32 or 42 so as to permit visualization of the orientation of the occluder 20 using fluoroscopy. Alternatively, other types of markers may be used, e.g., coatings, clips, etc. As will be readily understood by one skilled in the art, the orientation of a non-symmetrical occluder 20 during delivery is of great importance. Of course, when a non-symmetrical occluder 20 is used, the periphery of the occluder 20 may be configured such that the clamping force applied by the proximal side 40 is directly opposed to that applied by the distal side 30.
Upon deployment in vivo (a process described in detail below), an occluder according to the present invention applies a compressive force to the overlapping layers of septal tissue 12, i.e., septum primum 14 and septum secundum 16. Distal side 30 is seated against the septal tissue 12 in the left atrium 13; joint 22 extends through passage 18; and proximal side 40 is seated against the septal tissue 12 in the right atrium 11. As illustrated in
Moreover, loops 32 and 42 are configured to provide occluder 20 with adequate surface area to seal the PFO. For example, the broad configuration of loops 32 and 42 increases the surface area of occluder 20. Thus, loops 32 and 42 provide sealing along a large circumference around the passage 18 (i.e., the PFO), thereby minimizing the possibility of leakage between the right 11 and left 13 atria.
While configured to provide sufficient circumferential sealing, loops 32 and 42 are also configured to minimize the trauma they inflict on the septal tissue 12 surrounding the PFO. Specifically, two features of loops 32 and 42 achieve this. First, the peripheries of loops 32 and 42 may be rounded. Second, the peripheries of loops 32 and 42 are formed of a single wire and are, therefore, more flexible than the interiorly-located, connected, adjacent segments, which are formed of two wires. These features minimize the overall trauma inflicted by occluder 20 on the septal tissue 12 surrounding the PFO. Accordingly, occluder 20 has a low compression resistance. As used herein, “compression resistance” refers to the ability of an occluder 20 to resist the lateral compressive force applied by the heart as it contracts during a heartbeat. Generally, an occluder that resists compressive force, i.e., has high compression resistance, is undesirable because its rigid configuration may cause trauma to the septal tissue 12, the right atrium 11, and/or the left atrium 13.
In heretofore known occluder designs, dislodgement resistance must usually be sacrificed in order to improve, i.e., minimize, compression resistance. However, the occluder 20 according to the present invention possesses both increased dislodgement resistance and minimized compression resistance. These desirable attributes are achieved by the unique combination of radially-extending, connected, adjacent segments and peripheral loops 32 and 42 discussed above. The radially-extending, connected, adjacent segments (i.e., struts) increase the stiffness and, correspondingly, the dislodgment resistance of the occluder 20. The atraumatic shape of the peripheral loops 32 and 42 decreases the compression resistance of the occluder 20. In effect, because the struts are formed of double-stranded wire and the peripheries of the loops 32 and 42 are formed of single-stranded wire, the center of the occluder 20 is twice as strong as its parameter. This, correspondingly, produces the advantageous combination of increased dislodgement resistance and minimized compression resistance in occluder 20.
The dislodgement resistance of occluder 20 may be further increased without increasing the compression resistance by the inclusion of additional struts. As illustrated in
The configuration of the occluder 20 according to the present invention provides several further advantages. First, broad loops 32 and 42 create a large surface area for occluder 20 and thereby anchor the occluder 20 more securely in vivo. In contrast, many previously known occluders include narrow loops, which afford less surface area for exertion of compressive forces and secure placement of the occluder 20. Second, the loops 32 and 42 create an occlusion perimeter that likely extends significantly beyond the passage 18. Third, loops 32 and 42 are non-overlapping, i.e., the wires are not intertwined or weaved. This non-overlapping configuration reduces the occurrence of fretting corrosion, which frequently occurs in prior art devices containing overlapping wires.
Occluder 20 may be modified in various ways. According to some embodiments of the present invention, loops 32 of distal side 30 and loops 42 of proximal side 40 may be formed in a variety of shapes. Four examples are illustrated in
An alternative, diamond pattern 100b is shown in
Still a further alternative, rectangular pattern 100c, is shown in
Yet a further alternative, diamond pattern 100d, is shown in
Of course, distal 30 and proximal 40 sides of occluder 20 may be configured in a combination of shapes and sizes depending on clinical needs presented by a given PFO. If required, the loops 102 in the illustrative patterns provided in
According to further embodiments of the present invention, smaller loops may be included on distal side 30 and/or proximal side 40 of occluder 20 to increase the compressive force applied in close proximity to passage 18 (i.e., the PFO). As illustrated in
According to still further embodiments of the present invention and as illustrated in
Adjacent segments may be stitched to tissue scaffold 125 so as to securely fasten the scaffold 125 to occluder 20. For example,
According to yet further embodiments of the present invention, the configuration of occluder 20 may be modified to produce the low-profile occluder 130 shown in
Finally, although occluders according to the present invention have been heretofore described as including distal 30 and proximal 40 sides having different configurations, an occluder 20 according to the present invention may, alternatively, include distal 30 and proximal 40 sides having identical configurations. This identical design may provide several advantages, including ease of manufacture. Furthermore, any of the configurations described herein for either distal side 30 or proximal side 40 may be applied to either or both of distal side 30 and proximal side 40 of occluder 20.
An occluder as described herein may be delivered to a septal defect using any of several suitable delivery techniques, two of which will be described herein. In the first delivery technique, shown in
In a second delivery technique, shown in
Delivery wire 161 may be used to reposition and/or retrieve occluder 20 as shown in
In some embodiments according to the present invention, occluder 20 may be repositioned and/or retrieved using the alternative technique shown in
One skilled in the art would recognize that the occluders described herein may be used with anti-thrombogenic compounds, including but not limited to heparin and peptides, to reduce thrombogenicity of the occluder and/or to enhance the healing response of the septal tissue 12 following deployment of the occluder in vivo. Similarly, the occluders described herein may be used to deliver other drugs or pharmaceutical agents (e.g., growth factors, peptides). The anti-thrombogenic compounds, drugs, and/or pharmaceutical agents may be included in the occluders of the present invention in several ways, including by incorporation into the tissue scaffold 125, as previously described, or as a coating, e.g., a polymeric coating, on the wire(s) forming the distal 30 and proximal 40 sides of the occluder. Furthermore, the occluders described herein may include cells that have been seeded within tissue scaffold 125 or coated upon the wire(s) forming the distal 30 and proximal 40 sides of the occluder,
One skilled in the art would recognize that occluders according to this invention could be used in occluding other vascular and non-vascular openings. For example, the device could be inserted into a left atrial appendage or other tunnels or tubular openings within the body.
Having described preferred embodiments of the invention, it should be apparent that various modifications may be made without departing from the spirit and scope of the invention, which is defined in the claims below.
This application is a continuation application of U.S. application Ser. No. 12/210,897 filed Sep. 15, 2008, now issued as U.S. Pat. No. 8,784,448; which is a continuation application of U.S. application Ser. No. 10/455,572 filed Jun. 5, 2003, now issued as U.S. Pat. No. 7,431,729; which claims the benefit under 35 USC §119(e) to U.S. Application Ser. No. 60/386,327 filed Jun. 5, 2002. The disclosure of each of the prior applications is considered part of and is incorporated by reference in the disclosure of this application.
Number | Name | Date | Kind |
---|---|---|---|
3344048 | Kobetz et al. | Sep 1967 | A |
3824631 | Burstein et al. | Jul 1974 | A |
3874388 | King et al. | Apr 1975 | A |
3875648 | Bone | Apr 1975 | A |
3924631 | Mancusi | Dec 1975 | A |
4006747 | Kronenthal et al. | Feb 1977 | A |
4007743 | Blake | Feb 1977 | A |
4149327 | Hammer et al. | Apr 1979 | A |
4425908 | Simon | Jan 1984 | A |
4610674 | Suzuki et al. | Sep 1986 | A |
4626245 | Weinstein | Dec 1986 | A |
4693249 | Schenck et al. | Sep 1987 | A |
4696300 | Anderson | Sep 1987 | A |
4710181 | Fuqua | Dec 1987 | A |
4710192 | Liotta et al. | Dec 1987 | A |
4738666 | Fuqua | Apr 1988 | A |
4836204 | Landymore et al. | Jun 1989 | A |
4840623 | Quackenbush | Jun 1989 | A |
4902508 | Badylak et al. | Feb 1990 | A |
4915107 | Rebuffat et al. | Apr 1990 | A |
4917089 | Sideris | Apr 1990 | A |
4921479 | Grayzel | May 1990 | A |
4956178 | Badylak et al. | Sep 1990 | A |
5021059 | Kensey et al. | Jun 1991 | A |
5037433 | Wilk et al. | Aug 1991 | A |
5041129 | Hayhurst et al. | Aug 1991 | A |
5049131 | Deuss | Sep 1991 | A |
5078736 | Behl | Jan 1992 | A |
5106913 | Yamaguchi et al. | Apr 1992 | A |
5108420 | Marks | Apr 1992 | A |
5149327 | Oshiyama | Sep 1992 | A |
5163131 | Row et al. | Nov 1992 | A |
5167363 | Adkinson et al. | Dec 1992 | A |
5167637 | Okada et al. | Dec 1992 | A |
5171259 | Inoue | Dec 1992 | A |
5176659 | Mancini | Jan 1993 | A |
5192301 | Kamiya et al. | Mar 1993 | A |
5222974 | Kensey et al. | Jun 1993 | A |
5226879 | Ensminger et al. | Jul 1993 | A |
5236440 | Hlavacek | Aug 1993 | A |
5245023 | Peoples et al. | Sep 1993 | A |
5245080 | Aubard et al. | Sep 1993 | A |
5250430 | Peoples et al. | Oct 1993 | A |
5257637 | El Gazayerli | Nov 1993 | A |
5275826 | Badylak et al. | Jan 1994 | A |
5282827 | Kensey et al. | Feb 1994 | A |
5284488 | Sideris | Feb 1994 | A |
5304184 | Hathaway et al. | Apr 1994 | A |
5312341 | Turf | May 1994 | A |
5312435 | Nash et al. | May 1994 | A |
5316262 | Koebler | May 1994 | A |
5320611 | Bonutti et al. | Jun 1994 | A |
5334217 | Das | Aug 1994 | A |
5350363 | Goode et al. | Sep 1994 | A |
5350399 | Erlebacher et al. | Sep 1994 | A |
5354308 | Simon et al. | Oct 1994 | A |
5364356 | Hofling | Nov 1994 | A |
5411481 | Allen et al. | May 1995 | A |
5413584 | Schulze | May 1995 | A |
5417699 | Klein et al. | May 1995 | A |
5425744 | Fagan et al. | Jun 1995 | A |
5433727 | Sideris | Jul 1995 | A |
5451235 | Lock et al. | Sep 1995 | A |
5453099 | Lee et al. | Sep 1995 | A |
5478353 | Yoon | Dec 1995 | A |
5480353 | Garza, Jr. | Jan 1996 | A |
5480424 | Cox | Jan 1996 | A |
5486193 | Bourne et al. | Jan 1996 | A |
5507811 | Koike et al. | Apr 1996 | A |
5534432 | Peoples et al. | Jul 1996 | A |
5540712 | Kleshinski et al. | Jul 1996 | A |
5562632 | Davila et al. | Oct 1996 | A |
5577299 | Thompson et al. | Nov 1996 | A |
5601571 | Moss | Feb 1997 | A |
5603703 | Elsberry et al. | Feb 1997 | A |
5618311 | Gryskiewicz | Apr 1997 | A |
5620461 | Muijs Van De Moer et al. | Apr 1997 | A |
5626599 | Bourne et al. | May 1997 | A |
5634936 | Linden et al. | Jun 1997 | A |
5649950 | Bourne et al. | Jul 1997 | A |
5649959 | Hannam et al. | Jul 1997 | A |
5663063 | Peoples et al. | Sep 1997 | A |
5683411 | Kavteladze et al. | Nov 1997 | A |
5690674 | Diaz | Nov 1997 | A |
5693085 | Bulrge et al. | Dec 1997 | A |
5702421 | Schneidt | Dec 1997 | A |
5709707 | Lock et al. | Jan 1998 | A |
5713864 | Verkaart | Feb 1998 | A |
5717259 | Schexnayder | Feb 1998 | A |
5720754 | Middleman et al. | Feb 1998 | A |
5725552 | Kotula et al. | Mar 1998 | A |
5733294 | Forber et al. | Mar 1998 | A |
5733337 | Carr, Jr. et al. | Mar 1998 | A |
5741297 | Simon | Apr 1998 | A |
5772641 | Wilson | Jun 1998 | A |
5776162 | Kleshinski | Jul 1998 | A |
5776183 | Kanesaka et al. | Jul 1998 | A |
5797960 | Stevens et al. | Aug 1998 | A |
5800516 | Fine et al. | Sep 1998 | A |
5810884 | Kim | Sep 1998 | A |
5820594 | Fontirroche et al. | Oct 1998 | A |
5823956 | Roth et al. | Oct 1998 | A |
5829447 | Stevens et al. | Nov 1998 | A |
5853420 | Chevillon et al. | Dec 1998 | A |
5853422 | Huebsch et al. | Dec 1998 | A |
5855614 | Stevens et al. | Jan 1999 | A |
5861003 | Latson et al. | Jan 1999 | A |
5865791 | Whayne et al. | Feb 1999 | A |
5879366 | Shaw et al. | Mar 1999 | A |
5893856 | Jacob et al. | Apr 1999 | A |
5902287 | Martin | May 1999 | A |
5902319 | Daley | May 1999 | A |
5904703 | Gilson | May 1999 | A |
5919200 | Stambaugh et al. | Jul 1999 | A |
5924424 | Stevens et al. | Jul 1999 | A |
5928250 | Koike et al. | Jul 1999 | A |
5944738 | Amplatz et al. | Aug 1999 | A |
5955110 | Patel et al. | Sep 1999 | A |
5976174 | Ruiz | Nov 1999 | A |
5989268 | Pugsley, Jr. et al. | Nov 1999 | A |
5993475 | Lin et al. | Nov 1999 | A |
5993844 | Abraham et al. | Nov 1999 | A |
5997575 | Whitson et al. | Dec 1999 | A |
6010517 | Baccaro | Jan 2000 | A |
6024756 | Huebsch et al. | Feb 2000 | A |
6030007 | Bassily et al. | Feb 2000 | A |
6056760 | Koike et al. | May 2000 | A |
6071998 | Muller et al. | Jun 2000 | A |
6077291 | Das | Jun 2000 | A |
6077880 | Castillo et al. | Jun 2000 | A |
6079414 | Roth | Jun 2000 | A |
6080182 | Shaw et al. | Jun 2000 | A |
6096347 | Geddes et al. | Aug 2000 | A |
6108913 | Scarcfino et al. | Aug 2000 | A |
6113609 | Adams | Sep 2000 | A |
6117159 | Huebsch et al. | Sep 2000 | A |
6126686 | Badylak et al. | Oct 2000 | A |
6132438 | Fleischman et al. | Oct 2000 | A |
6143037 | Goldstein et al. | Nov 2000 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6165183 | Kuehn et al. | Dec 2000 | A |
6165204 | Levinson et al. | Dec 2000 | A |
6171329 | Shaw et al. | Jan 2001 | B1 |
6174322 | Schneidt | Jan 2001 | B1 |
6174330 | Stinson | Jan 2001 | B1 |
6187039 | Hiles et al. | Feb 2001 | B1 |
6190353 | Makower et al. | Feb 2001 | B1 |
6206895 | Levinson | Mar 2001 | B1 |
6206907 | Marino et al. | Mar 2001 | B1 |
6214029 | Thill et al. | Apr 2001 | B1 |
6217590 | Levinson | Apr 2001 | B1 |
6221092 | Koike et al. | Apr 2001 | B1 |
6227139 | Nguyen et al. | May 2001 | B1 |
6228097 | Levinson et al. | May 2001 | B1 |
6231561 | Frazier et al. | May 2001 | B1 |
6245080 | Levinson | Jun 2001 | B1 |
6245537 | Williams et al. | Jun 2001 | B1 |
6261309 | Urbanski | Jul 2001 | B1 |
6265333 | Dzenis et al. | Jul 2001 | B1 |
6270515 | Linden et al. | Aug 2001 | B1 |
6277138 | Levinson et al. | Aug 2001 | B1 |
6277139 | Levinson et al. | Aug 2001 | B1 |
6287317 | Makower et al. | Sep 2001 | B1 |
6290674 | Roue et al. | Sep 2001 | B1 |
6299635 | Frantzen | Oct 2001 | B1 |
6306150 | Levinson | Oct 2001 | B1 |
6306424 | Vyakamam et al. | Oct 2001 | B1 |
6312446 | Huebsch et al. | Nov 2001 | B1 |
6315791 | Gingras et al. | Nov 2001 | B1 |
6316262 | Huisman et al. | Nov 2001 | B1 |
6319263 | Levinson | Nov 2001 | B1 |
6322548 | Payne et al. | Nov 2001 | B1 |
6328727 | Frazier et al. | Dec 2001 | B1 |
6334872 | Termin et al. | Jan 2002 | B1 |
6342064 | Koike et al. | Jan 2002 | B1 |
6344048 | Chin et al. | Feb 2002 | B1 |
6344049 | Levinson et al. | Feb 2002 | B1 |
6346074 | Roth | Feb 2002 | B1 |
6348041 | Klint | Feb 2002 | B1 |
6352552 | Levinson et al. | Mar 2002 | B1 |
6355052 | Neuss et al. | Mar 2002 | B1 |
6356782 | Sirimanne et al. | Mar 2002 | B1 |
6364853 | French et al. | Apr 2002 | B1 |
6371904 | Sirimanne et al. | Apr 2002 | B1 |
6375625 | French et al. | Apr 2002 | B1 |
6375671 | Kobayashi et al. | Apr 2002 | B1 |
6379342 | Levinson | Apr 2002 | B1 |
6379368 | Corcoran et al. | Apr 2002 | B1 |
6387104 | Pugsley, Jr. et al. | May 2002 | B1 |
6398796 | Levinson | Jun 2002 | B2 |
6402772 | Amplatz et al. | Jun 2002 | B1 |
6419669 | Frazier et al. | Jul 2002 | B1 |
6426145 | Moroni | Jul 2002 | B1 |
6436088 | Frazier et al. | Aug 2002 | B2 |
6440152 | Gainor et al. | Aug 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6460749 | Levinson et al. | Oct 2002 | B1 |
6482224 | Michler et al. | Nov 2002 | B1 |
6488706 | Solymar | Dec 2002 | B1 |
6494888 | Laufer et al. | Dec 2002 | B1 |
6508828 | Akerfeldt et al. | Jan 2003 | B1 |
6514515 | Williams | Feb 2003 | B1 |
6548569 | Williams et al. | Apr 2003 | B1 |
6551303 | Van Tassel et al. | Apr 2003 | B1 |
6551344 | Thill | Apr 2003 | B2 |
6585755 | Jackson et al. | Jul 2003 | B2 |
6596013 | Yang et al. | Jul 2003 | B2 |
6599448 | Ehrhard, Jr. et al. | Jul 2003 | B1 |
6610764 | Martin et al. | Aug 2003 | B1 |
6623508 | Shaw et al. | Sep 2003 | B2 |
6623518 | Thompson et al. | Sep 2003 | B2 |
6626936 | Stinson | Sep 2003 | B2 |
6629901 | Huang | Oct 2003 | B2 |
6666861 | Grabek | Dec 2003 | B1 |
6669722 | Chen et al. | Dec 2003 | B2 |
6689589 | Huisman et al. | Feb 2004 | B2 |
6712804 | Roue et al. | Mar 2004 | B2 |
6712836 | Berg et al. | Mar 2004 | B1 |
6726696 | Houser et al. | Apr 2004 | B1 |
6828357 | Martin et al. | Dec 2004 | B1 |
6838493 | Williams et al. | Jan 2005 | B2 |
6867247 | Williams et al. | Mar 2005 | B2 |
6867248 | Martin et al. | Mar 2005 | B1 |
6867249 | Lee et al. | Mar 2005 | B2 |
6921410 | Porter | Jul 2005 | B2 |
7097653 | Freudenthal et al. | Aug 2006 | B2 |
7431729 | Chanduszko | Oct 2008 | B2 |
8430934 | Das | Apr 2013 | B2 |
8784448 | Chanduszko | Jul 2014 | B2 |
20010010481 | Blanc et al. | Aug 2001 | A1 |
20010014800 | Frazier et al. | Aug 2001 | A1 |
20010034537 | Shaw et al. | Oct 2001 | A1 |
20010034567 | Allen et al. | Oct 2001 | A1 |
20010037129 | Thill | Nov 2001 | A1 |
20010039435 | Roue et al. | Nov 2001 | A1 |
20010041914 | Frazier et al. | Nov 2001 | A1 |
20010041915 | Roue et al. | Nov 2001 | A1 |
20010044639 | Levinson | Nov 2001 | A1 |
20010049492 | Frazier et al. | Dec 2001 | A1 |
20020010481 | Jayaraman | Jan 2002 | A1 |
20020019648 | Akerfeldt et al. | Feb 2002 | A1 |
20020022859 | Hogendijk | Feb 2002 | A1 |
20020026208 | Roe et al. | Feb 2002 | A1 |
20020029048 | Miller | Mar 2002 | A1 |
20020032459 | Horzewski et al. | Mar 2002 | A1 |
20020032462 | Houser et al. | Mar 2002 | A1 |
20020034259 | Tada | Mar 2002 | A1 |
20020035374 | Botillo et al. | Mar 2002 | A1 |
20020043307 | Ishida et al. | Apr 2002 | A1 |
20020052572 | Franco et al. | May 2002 | A1 |
20020058989 | Chen et al. | May 2002 | A1 |
20020077555 | Schwartz | Jun 2002 | A1 |
20020095174 | Tsugita et al. | Jul 2002 | A1 |
20020096183 | Stevens et al. | Jul 2002 | A1 |
20020099389 | Michler et al. | Jul 2002 | A1 |
20020107531 | Schrock et al. | Aug 2002 | A1 |
20020111537 | Taylor et al. | Aug 2002 | A1 |
20020111637 | Kaplan et al. | Aug 2002 | A1 |
20020111647 | Khairkhahan et al. | Aug 2002 | A1 |
20020120323 | Thompson et al. | Aug 2002 | A1 |
20020128680 | Paviovic | Sep 2002 | A1 |
20020129819 | Feldman et al. | Sep 2002 | A1 |
20020164729 | Skraly et al. | Nov 2002 | A1 |
20020169377 | Khairkhahan et al. | Nov 2002 | A1 |
20020183786 | Girton | Dec 2002 | A1 |
20020183787 | Wahr et al. | Dec 2002 | A1 |
20020183823 | Pappu | Dec 2002 | A1 |
20020198563 | Gainor et al. | Dec 2002 | A1 |
20030004533 | Dieck et al. | Jan 2003 | A1 |
20030023266 | Welch et al. | Jan 2003 | A1 |
20030028213 | Thill et al. | Feb 2003 | A1 |
20030045893 | Ginn | Mar 2003 | A1 |
20030050665 | Ginn | Mar 2003 | A1 |
20030055455 | Yang et al. | Mar 2003 | A1 |
20030057156 | Peterson et al. | Mar 2003 | A1 |
20030059640 | Marton et al. | Mar 2003 | A1 |
20030065379 | Babbas et al. | Apr 2003 | A1 |
20030100920 | Akin et al. | May 2003 | A1 |
20030120337 | Van Tassel et al. | Jun 2003 | A1 |
20030139819 | Beer et al. | Jul 2003 | A1 |
20030171774 | Freudenthal et al. | Sep 2003 | A1 |
20030191495 | Ryan et al. | Oct 2003 | A1 |
20030195530 | Thill | Oct 2003 | A1 |
20030204203 | Khairithahan et al. | Oct 2003 | A1 |
20040044361 | Frazier et al. | Mar 2004 | A1 |
20040073242 | Chanduszko | Apr 2004 | A1 |
20040176799 | Chanduszko et al. | Sep 2004 | A1 |
20040210301 | Obermiller | Oct 2004 | A1 |
20040234567 | Dawson | Nov 2004 | A1 |
20050025809 | Hasirci et al. | Feb 2005 | A1 |
20050043759 | Chanduszko | Feb 2005 | A1 |
20050113868 | Devellian | May 2005 | A1 |
20050267523 | Devellian et al. | Dec 2005 | A1 |
20050273135 | Chanduszko et al. | Dec 2005 | A1 |
20050288786 | Chanduszko | Dec 2005 | A1 |
20060122647 | Callaghan et al. | Jun 2006 | A1 |
20060265004 | Callaghan et al. | Nov 2006 | A1 |
20070010851 | Chanduszko et al. | Jan 2007 | A1 |
20070167981 | Opolski | Jul 2007 | A1 |
Number | Date | Country |
---|---|---|
9413645 | Oct 1994 | DE |
0362113 | Apr 1990 | EP |
0474887 | Mar 1992 | EP |
0 839 549 | May 1998 | EP |
0 861 632 | Sep 1998 | EP |
1013227 | Jun 2000 | EP |
1046375 | Oct 2000 | EP |
1222897 | Jul 2002 | EP |
WO-9625179 | Aug 1996 | WO |
WO-9631157 | Oct 1996 | WO |
WO-9807375 | Feb 1998 | WO |
WO-9808462 | Mar 1998 | WO |
WO-9816174 | Apr 1998 | WO |
WO-9829026 | Jul 1998 | WO |
WO-9851812 | Nov 1998 | WO |
WO-9905977 | Feb 1999 | WO |
WO-9918862 | Apr 1999 | WO |
WO-9918864 | Apr 1999 | WO |
WO-9918870 | Apr 1999 | WO |
WO-9918871 | Apr 1999 | WO |
W0-9930640 | Jun 1999 | WO |
WO-0027292 | May 2000 | WO |
WO-0044428 | Aug 2000 | WO |
WO-0108600 | Feb 2001 | WO |
WO-0119256 | Mar 2001 | WO |
WO-0121247 | Mar 2001 | WO |
WO-0128432 | Apr 2001 | WO |
WO-0130268 | May 2001 | WO |
WO-0149185 | Jul 2001 | WO |
WO-0178596 | Oct 2001 | WO |
WO-0193783 | Dec 2001 | WO |
WO-0217809 | Mar 2002 | WO |
WO-0224106 | Mar 2002 | WO |
WO-03024337 | Mar 2003 | WO |
WO-03053493 | Jul 2003 | WO |
WO-03053493 | Jul 2003 | WO |
WO-03059152 | Jul 2003 | WO |
WO-03063732 | Aug 2003 | WO |
WO-03077733 | Sep 2003 | WO |
WO-03171774 | Sep 2003 | WO |
WO-03082076 | Oct 2003 | WO |
WO-03103476 | Dec 2003 | WO |
WO-2004032993 | Apr 2004 | WO |
WO-2004037333 | May 2004 | WO |
WO-2004043266 | May 2004 | WO |
WO-2004043508 | May 2004 | WO |
WO-2004052213 | Jun 2004 | WO |
WO-2005006990 | Jan 2005 | WO |
WO-2005018728 | Mar 2005 | WO |
WO-2005027752 | Mar 2005 | WO |
WO-2005074813 | Aug 2005 | WO |
WO-2005092203 | Oct 2005 | WO |
WO-2005110240 | Nov 2005 | WO |
WO-2005112779 | Dec 2005 | WO |
WO-2006036837 | Apr 2006 | WO |
WO-2006102213 | Sep 2006 | WO |
Entry |
---|
Athanasion; T., “Coronary Artery Bypass with the Use of a Magnetic Distal Anastomotic Device: Surgical Technique and Preliminary Experience,” The Heart Surgery Forum #2004-1024, 2004, 4 pgs. |
Bachthaler, M. et al., “Corrosion of Tungsten Coils After Peripheral Vascular Embolization Theraphy: Influence on Outcome and Tungsten Load”, Catherization and Cardiovascular Interventions, vol. 62; pp, 380-384, 2004. |
European Examination Report, European Application No. 04781644.2, mailed Aug. 23, 2007 (3 Pages). |
Falk, V., “Facilitated Endoscopic Beating Heart Coronary Artery Bypass Grafting Using a Magentic Coupling Device,” Journal of Thoracic and Cardiovascular Surgery, vol. 126,(5), pp. 1575-1579, 2003. |
Filsoufi, F., et al., “Automated Distal Coronary Bypass with a Novel Magnetic Coupler (MVP system),” J. Thoracic and Cardiovascular Surgery, vol. 127(1), pp. 185-192, 2004. |
International Search Report for International Patent Application No. PCT/AU03/00759, filed Jun. 19, 2003. |
International Search Report, International Application No. PCT/US02/40850 mailed Jun. 19, 2003 (4 pgs). |
International Search Report, International Application No. PCT/US03/01050, mailed Jul. 8, 2003 (1 pg). |
International Search Report, International Application No. PCT/US03/09051, mailed Sep. 29, 2003 (2 pgs). |
International Search Report, international Application No. PCT/US03/17390, mailed Oct. 6, 2003 (4 pgs). |
International Search Report, International Application No. PCT/US05/006703, mailed Jul. 25, 2005 (3 pgs). |
International Search Report, International Application No. PCT/US05/013705 mailed Aug. 4, 2005 (4 pgs). |
International Search Report, International Application No. PCT/US05/015382, mailed Oct. 6, 2005 (4 pgs). |
International Search Report, International Application No. PCT/US05/34276, mailed Oct. 9, 2007. |
International Search Report, International Application No. PCT/US03/17715, mailed Mar. 24, 2004 (2 pgs). |
International Search Report, International Application No. PCT/US07/065546, mailed Oct. 29, 2007. 4 pages. |
International Search Report, International Application No. PCT/US2007/065526, mailed Aug. 8, 2007 (5 pgs). |
International Search Report, International Application No. PCT/US2007/065541, mailed Aug. 7, 2007 (4 pgs). |
International Search Report, International Application No. PCT/US97/14822, mailed Feb. 20, 1998 (2 pgs). |
International Search Report, International Application No. PCT/US97/17927, mailed Feb. 10, 1998 (1 pg). |
Isotalo, T. et al., “Biocompatibility Testing of a New Bioabsorbable X-Ray Positive SR-PLA 96/4 Urethral Stent”, The Journal of Urology, vol. 163, pp. 1764-1767, Nov. 1999. |
Kimura, A., et al., “Effects of Neutron Irradiation on the Transformation Behavior in Ti—Ni Alloys,” Abstract, Proceedings of the Intl Conf. on Mariensitic Transformations, 1992, pp. 935940. |
Klima, U., “Magnetic Vascular Port in Minimally Invasive Direct Coronary Artery Bypass Grafting,” Circulation, 2004, 11-55-11-60. |
Meier, MD, Bernhard et al., “Contemporary Management of Patent Foramen Ovate,” American Heart Association, Inc., Circulation, 2003, vol. 107, pp. 5-9. |
Nat'l Aeronautics and Space Administration, “55-Nitinol—The Alloy with a Memory: Its Physical Metallurgy, Properties and Applications,” NASA Report, pp. 24-25. |
Parviainen, M. et al., “A New Biodegradable Stent for the Pancreaticojejunal Anastomosis After Pancreaticoduodenal Resection: In Vitro Examination and Pilot Experiences in Humans”, Pancreas, vol. 21, No. 1, pp. 14-21, 2000. |
Ramanathan, G., et al., “Experimental and Computational Methods for Shape Memory Alloys,” 15th ASCE Engineering Mechanics Conference, Jun. 2-5, 2002. |
Ruddy, A.C. et al., “Rheological, Mechanical and Thermal Behaviour of Radipaque Filled Polymers”, Polymer Processing Research Centre, School of Chemical Engineering, Queen's University of Belfast , 5 pages. |
Ruiz, et al, “The Puncture Technique: A New Method for Transcatheter Closure of Patent Foramen Ovale,” Catheterization and Cardiovascular Interventions, 2001, vol. 53, pp. 369-372. |
Shabalovskaya, S., “Surface, Corrosion amd Biocompatibility Aspects of Nitinol as and Implant Material,” Bio-Medical Materials and Engineering, 2002, vol. 12, pp. 69-109. |
SMST-2000; “Proceedings of the International Conference on Shape Memory and Superelastic Technologies,” Apr. 30-May 4, 2000, Asilomar Conference Center. |
Stockel, “Nitinol Medical Devices and Implants,” SMST-2000 Conference Proceedings, 2001, pp. 531-541. |
Uchil, J., “Shape Memory Alloys—Characterization Techniques,” Pramana—Journal of Physics, 2002, vol. 58(5)(6), pp. 1131-1139. |
Vaajanen, A. et al., “Expansion and Fixation Properties of a New Braided Biodegradable Urethral Stent: An-Experimental Study in the Rabbit”, The Journal of Urology, vol. 169; pp. 1771-1174, Mar. 2003. |
International Search Report, International Application No. PCT/US03/32133, mailed Apr. 22, 2004 (1 pg). |
International Search Report, International Application No. PCT/US03/34003 mailed Oct. 3, 2004 (4 pgs). |
International Search Report, International Application No. PCT/US03/35998 mailed Jun. 16, 2004 (5 pgs). |
International Search Report, International Application No. PCT/US03/39253, mailed Apr. 19, 2004 (4 pgs). |
International Search Report, International Application No. PCT/USO4/022643, mailed Mar. 31, 2005 (2 pgs). |
International Search Report, International Application No. PCT/USO4/026998, mailed Apr. 22, 2005 (5 pgs). |
European Search Report, European Application No. 03729663.9, mailed Feb. 20, 2008 (3 Pages). |
European Examination Report, European Application No. 03779297.5, mailed Mar. 15, 2007 (6 Pages). |
International Search Report, International Application No. PCT/USO4/029978, mailed Jan. 26, 2005 (3 pgs). |
Number | Date | Country | |
---|---|---|---|
20140330310 A1 | Nov 2014 | US |
Number | Date | Country | |
---|---|---|---|
60386327 | Jun 2002 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12210897 | Sep 2008 | US |
Child | 14334387 | US | |
Parent | 10455572 | Jun 2003 | US |
Child | 12210897 | US |